Search
ciclosporin ophthalmic; cyclosporine A ophthalmic (Restasis, Cequa)
Tradenames: Restasis, Cequa:FDA-approved Aug 2018
Indications:
- severe keratitis in adults with xerophthalmia (NICE) [NGC]
Contraindications:
- not for moderate dry eyes (xerophthalmia) [2]
Dosage:
- apply BID Cequa: 0.09% cyclosporine A ophthalmic
Notes:
- Restasis: $175/month (2003) [1]
Interactions
drug adverse effects of immunosuppressive agents
monitor with immunosuppressive agents
General
cyclosporin A (Sandimmune, Neoral [CsA])
ophthalmic agent (eyedrops)
References
- Prescriber's Letter 10(4):23 2003
- Therapeutics Letter #108. Therapeutics Initiative
Drugs to Avoid.
http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/